Neosens

What Neosens does

NEOSENS is a Swiss deep-tech startup incorporated in February 2024 and headquartered at the EPFL BIOS Laboratory in Lausanne. The company develops a portable, label-free biosensing platform built on nanophotonics and plasmonics technology originated from EPFL's Bionanophotonic Systems Laboratory. The platform combines a field-ready reader device with interchangeable single-use cartridges designed to detect different substances (initially cyanotoxins for water-quality monitoring) and is supported by data management tools that store measurement results together with time and location information. The underlying sensing approach builds on peer-reviewed research published in ACS Nano (2018) and Small (2020) by the BIOS Lab team, with Prof. Hatice Altug serving as scientific advisor.

The company is led by a four-person core team — CEO & Founder Marco Fumagalli (EPFL MSc in Biomedical Engineering), CTO Dr. Abtin Saateh (PhD at BIOS, EPFL), CFO Michael Stegmaier (Esade MSc, ex-EY), and Head of Growth Leandro Flematti (Bocconi MSc, European institutional sales experience). Its go-to-market is B2B and sales-led, targeting environmental monitoring (water quality, harmful algal bloom and cyanotoxin detection) as the primary use case, with stated secondary applications in food safety, agricultural and livestock monitoring, clinical and point-of-care diagnostics, and industrial process control. Revenue mechanics are anchored on hardware sales of the reader device paired with recurring single-use cartridge replacement, although no pricing, commercial customers, or revenue figures have been publicly disclosed.

To date, all identified funding has been non-dilutive. Neosens has secured an Innosuisse Innovation Project grant (with CSEM as implementation partner), completed an Innocheque project with CSEM advancing the single-use cartridge design, and is supported institutionally by EPFL, CSEM, SUPSI Startup Garage, Canton Ticino, FIT, Venture Kick, Start Lausanne, and Vaud. No equity funding rounds have been disclosed, and the company remains founder-led at the pre-commercialization stage, with the cartridge currently advancing toward final design.

Name

Neosens

Legal name

NEOSENS

Website

https://neosens-dx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

NEOSENS is a Swiss deep-tech startup that has built a portable, lab-precise biosensing platform based on nanophotonics and plasmonics technology, targeting on-site environmental monitoring, food safety, and clinical diagnostics applications.

Ownership category

akta.pro rank

Product category

Biosensors

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Nanotechnology (541713), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Analytical Instruments (3826), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

Keywords

• Biosensing technology
• Environmental monitoring
• Water quality sensors
• Plasmonic biosensors
• Portable diagnostic devices

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Biosensor Hardware and Cartridges: Sale of portable biosensor devices and interchangeable single-use cartridges for various detection applications. Revenue likely generated through device sales and recurring cartridge revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Neosens develops and sells a portable biosensing platform built on nanophotonics and plasmonics-based detection technology for on-site environmental monitoring. The core offering consists of a field-ready biosensor device with interchangeable single-use cartridges tailored to detect specific substances (e.g., cyanotoxins for water quality), supported by data management tools that store, visualize, and analyze measurements with time and location tagging.

Product overview

Neosens offers an advanced biosensing platform designed for portable, on-site environmental monitoring. The core offering consists of a user-friendly biosensing platform with interchangeable single-use cartridges that detect different substances based on monitoring needs (e.g., cyanotoxins for water quality), supported by data management tools for storing, visualizing, and analyzing measurements with time and location data.

Differentiator

Problem solved

Functional benefit

Products and services

• Biosensing Platform A user-friendly, portable biosensing platform designed to deliver consistent results with a simple workflow, allowing routine measurements to be performed reliably by non-specialist users for on-site detection of substances including cyanotoxins.
• Interchangeable Biosensor Cartridges Single-use biosensor cartridges with interchangeable formats that enable the detection of different substances depending on monitoring needs, designed for environmental monitoring applications including water quality and cyanotoxin detection.

Quantifiable outcome

• Enables routine environmental monitoring where traditional lab testing would be too slow or impractical

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• EPFL BIOS LabcoreStrategic or Co-development PartnerBionanophotonic Systems Laboratory provides cutting-edge infrastructure, scientific expertise, network access, and technical/methodological support. Core technology originated from this lab. CEO Marco Fumagalli and CTO Dr. Abtin Saateh both obtained degrees from EPFL.
• CSEMcoreTechnology or IntegrationCollaboration with CSEM for hardware development. Completed Innocheque project advancing single-use cartridge concept. Strategic collaboration to advance portable biosensor platform for rapid on-site detection of cyanotoxins. CSEM serves as Implementation Partner in Innosuisse Innovation Project.
• SUPSI Startup GarageminorStrategic or Co-development PartnerProvides support, mentorship and network access through their startup ecosystem for early-stage development.
• Canton TicinominorStrategic or Co-development PartnerSupports with sample access through a comparative study with Canton Ticino, providing real-world testing data for technology validation.

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Bio-Rad Laboratories: Large global life science tools and clinical diagnostics company offering analytical instruments, reagents, and laboratory services across many categories. Comparable end-use cases (analytical measurements) and broad life sciences/clinical customer base, though operating at much larger scale across a wider portfolio.
• Hologic: Major clinical diagnostics company with strong molecular diagnostics and women's health franchises (e.g., Panther, Aptima). Comparable in the clinical diagnostics end-market and biomarker-based testing ambition, though Hologic operates a much broader diagnostics portfolio at enterprise scale.
• Abbott Point of Care: Major point-of-care diagnostics business with the i-STAT system, delivering rapid results outside the central laboratory by non-specialist users. Comparable POC philosophy (fast, accurate results for non-specialists) and overlapping clinical diagnostics target customers, though at much greater scale.

Direct peers

• Quanterix: US-based life sciences company operating the Simoa single-molecule immunoassay platform for ultra-sensitive digital biomarker detection. Comparable 'digital biomarker detection' positioning and overlapping target markets in clinical diagnostics and life science research.
• Nicoya Lifesciences: Canadian company developing SPR/plasmonic-based benchtop biosensor instruments (e.g., OpenSPR, Alto) for life science research. Directly comparable to Neosens because both leverage plasmonic biosensing for label-free molecular detection and target overlapping research and diagnostics customers.
• Carterra: US company developing label-free, high-throughput SPR-based biosensor instruments (e.g., LSA, CA, Klee) for antibody characterization and binding kinetics. Comparable label-free plasmonic detection technology with a similar life-science research customer base.
• Genalyte: San Diego-based company operating a silicon photonic biosensor platform with disposable cartridges for multiplex immunoassays. Directly comparable: photonic biosensing technology, cartridge-based consumables, and clinical diagnostics end-market.
• Fluidic Analytics: UK-based company building microfluidic, label-free protein interaction and conformational analysis instruments. Comparable label-free protein analytics technology and shared life science research customer base with Neosens' plasmonic detection approach.
• Cytiva (Biacore): Division of Cytiva (Danaher) that commercializes the long-established Biacore line of label-free SPR biosensors for biomolecular interaction analysis. Directly comparable technology foundation (label-free plasmonic detection) and shared aim of replacing slower, more complex analytical techniques.

Others

• Kibron: Finnish company specializing in water quality testing equipment using surface tension and other detection methods. Comparable customer base in water quality monitoring and environmental laboratories, though it uses different sensing modalities and serves the same end-users without direct biosensing overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/neosenstechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neosens